Simple Summary Neo-adjuvant systemic (NAS) therapy for melanoma is leading the way in
immunotherapy for oncology. There is both a strong biological rationale to support NAS …

Patients with stage III resectable melanoma carry a high risk of melanoma recurrence that
ranges from approximately 40% to 90% at 5 years following surgical management alone …

Opinion statement Patients with clinical stage III melanoma, defined as palpable lymph
nodes with or without in-transit metastases, have poor prognosis even with recent advances …

The landscape of treatment options and outcomes for patients with locally advanced and
metastatic melanoma has changed dramatically in the past decade, with the introduction of …

9581 Background: For several cancers, response to neoadjuvant therapy (NAT) correlates
with survival. Targeted and immune therapies achieve high response rates and durable …

Survival of macroscopic stage III melanoma is poor. Five-year overall survival and relapse-
free survival rates for surgery alone range from 40 to 59% and 30 to–39%, respectively. The …

Clinical stage III melanoma, defined as resectable RECIST measurable nodal disease with
or without in-transit metastases, represents approximately 15% of new melanoma diagnoses …

The association among pathological response, recurrence-free survival (RFS) and overall
survival (OS) with neoadjuvant therapy in melanoma remains unclear. In this study, we …

Locally/regionally advanced melanoma confers a major challenge in terms of surgical and
medical management. Surgical treatment carries the risks of surgical morbidities and …

The role of neoadjuvant therapy is undergoing an historic shift in oncology. The emergence
of potent immunostimulatory anticancer agents has transformed neoadjuvant therapy from a …